摘要
目的了解不同亚型急性髓系白血病（AML）患者TAK1、p38基因的表达差异，并分析TAK1、p38基因不同表达水平患者的临床特征。方法以GAPDH为内参，14名健康人为对照组，采用实时定量聚合酶链反应方法检测87例AML患者骨髓TAK1、p38基因的表达，对结果进行统计学分析。结果AML患者TAK1、p38基因表达均高于对照组（相对表达量：0．194±0．125比0．015±0．008，0．233±0．140比0．010．±0．005，均P〈0．001）。M4患者TAKImRNA表达高于M2、M3、M5（P=0．005、0．000、0．002），M2高于M3（P=0．022）；M4患者p38mRNA表达高于Ml、M2、M3、M5（P=0．013、0．035、0．000、0．045），M2高于M，（P=0．001），M，高于M，（P=0．012）。TAK1高表达组CD56阳性率、外周血白细胞数均高于TAK1低表达组，p38低表达组CDl9阳性率高于p38高表达组，差异均有统计学意义（均P〈0．05）。结论AML患者TAK1、1338基因表达升高，其表达上调可能在AML发病中起重要作用。
Objective To investigate the expression levels of TAK1 and p38 genes among different subtypes of acute myeloid leukemia （AML） patients, and to analyze the clinical characteristics of patients with different expression levels of TAK1 and p38 genes. Methods GAPDH was made as an internal reference, 14 healthy people as control group. The quantitative real-time PCR was used to detect the expression of TAK1 and p38 in bone marrow samples of 87 AML patients, and the results were analyzed statistically. Results The expression levels of TAK1 and p38 in experiment group were higher than those in control group （0.194± 0.125 vs 0.015±0.008, 0.233±0.140 vs 0.010±0.005, P 〈 0.001）. TAK1 expression in M4 was higher than that in M2, M3 and M5 （P = 0.005, 0.000, 0.002）, TAK1 expression in M3 was lower than that in M2 （P = 0.022）. p38 expression in Mr was higher than that in M1, M2, M3 and M5 （P = 0.013, 0.035, 0.000, 0.045）, as it was higher in M2 and M5 than that in M3 （P = 0.001, 0.012）. The CD56 positive rate cells and the number of peripheral blood leukocytes of the TAK1 high expression group were higher than those of the TAK1 low expression group, the CD19 positive rate of the p38 low expression group was higher than that of the p38 high expression group. Conclusion The expression levels of TAK1 and p38 genes are elevated in AML patients, and the up-regulation may play an important role in the pathogenesis of AML.
出处
《白血病．淋巴瘤》
CAS
2015年第11期658-661,共4页
Journal of Leukemia & Lymphoma
基金
国家自然科学基金（81170520）
